Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evidence-based and value-based formulary guidelines.

Peter J Neumann1

  • 1Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA.

Health Affairs (Project Hope)
|March 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness thresholds used in the United States vs most favored nations.

Health affairs scholar·2026
Same author

FDA approvals of specialty drugs, 2000-2024.

Health affairs scholar·2026
Same author

Communication of launch prices by drug companies, 2022-2024.

The American journal of managed care·2026
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

When Do Published Cost-Effectiveness Analyses Include Societal Costs? An Empirical Analysis, 2013-2023.

Medical decision making : an international journal of the Society for Medical Decision Making·2025
Same journal

National Health Expenditure Projections, 2025-34: Strong Utilization Growth Initially, Legislative Impacts Later.

Health affairs (Project Hope)·2026
Same journal

State Medicaid Programs Face Increased Spending On Medicare Premiums.

Health affairs (Project Hope)·2026
Same journal

Not enough time.

Health affairs (Project Hope)·2026
Same journal

Medicaid Tobacco And Nicotine Cessation Treatment Rates Remained Low, 2019-24.

Health affairs (Project Hope)·2026
Same journal

Third-Party Convener Firms And The Rise Of Geographically Dispersed, High-Earning Medicare ACOs.

Health affairs (Project Hope)·2026
Same journal

The Opacity Of Price Transparency.

Health affairs (Project Hope)·2026
See all related articles

Drug formulary decisions are becoming more transparent and scientifically rigorous with new guidelines from the Academy of Managed Care Pharmacy (AMCP). These standards require drug companies to submit comprehensive dossiers detailing drug value and comparative effectiveness.

Area of Science:

  • Health economics
  • Pharmaceutical policy
  • Clinical decision-making

Background:

  • Traditional drug formulary processes often lack transparency and scientific rigor.
  • Health plans and hospitals utilize drug formularies for medication management.
  • There is a growing need for standardized, evidence-based approaches in formulary decision-making.

Purpose of the Study:

  • To describe the Academy of Managed Care Pharmacy (AMCP) formulary guidelines.
  • To review the progress of implementing these new guidelines.
  • To analyze critical issues related to formulary management and future directions.

Main Methods:

  • Review of AMCP formulary guidelines.
  • Analysis of current implementation status and progress.

Related Experiment Videos

  • Identification and discussion of key challenges and future considerations in formulary decision-making.

    • Main Results:

    • AMCP guidelines promote standardized drug dossiers for formulary review.
    • These dossiers include data on drug effectiveness, safety, and economic value.
    • Implementation is increasing, but challenges remain in achieving full transparency and rigor.

    Conclusions:

    • The AMCP guidelines represent a significant step towards more transparent and scientifically sound drug formulary processes.
    • Standardized dossiers enhance the evaluation of drug value and comparative effectiveness.
    • Addressing future critical issues is essential for optimizing formulary management and healthcare outcomes.